Antibacterial molecular coatings pre-fabricated for biologic wound dressings
Antibacterial molecular coatings pre-fabricated for biologic wound dressings
批准号:
8648458
负责人:
Ankit Agarwal
金额:
$77.52万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-04-01 至 2016-06-30
关键词:
AnalgesicsAnionsAnti-Bacterial AgentsAntibioticsBedsBiological DressingsBurn TraumaBurn injuryCaringCessation of lifeChlorhexidineClinicalClinical TrialsCollaborationsDataData SetDepositionDermalDevelopmentDrug FormulationsEconomicsExudateFamily suidaeFeedbackFrequenciesGelHealedHealthHealthcareHumanImpaired wound healingIn VitroInfectionInfection preventionIonsLeadLegal patentLength of StayMarketingMechanicsMedicalMicrobeMicrofilmMicrofilmingMolecularMusNanotechnologyNursesOintmentsOperative Surgical ProceduresPainPatientsPhasePolymersProcessPropertyProteinsRecording of previous eventsResearchSavingsScientistSepsisSilverSmall Business Innovation Research GrantSolutionsStaining methodStainsSterile coveringsSurfaceSurgeonSurgical woundTechnologyTherapeutic UsesThickTimeTissue StainsTissuesTopical AntibioticTopical applicationToxic effectTranslational ResearchTraumaWaterWound HealingWound Infectionantimicrobialbactericidebasebiomaterial compatibilitycare burdencostcytotoxiccytotoxicitydesignhealinghealth care economicshealth economicsimprovedin vivoirritationkillingsmanufacturing scale-upmethicillin resistant Staphylococcus aureusmicrobial colonizationnanoparticlepathogenpreventstandard of caretissue regenerationtopical antisepticwound
中文摘要
描述(由申请人提供):烧伤、创伤和外科伤口的临床感染是巨大的经济和卫生保健负担。在美国,手术伤口的感染率为2-5%,烧伤伤口的感染率高达20%。目前的护理标准是密集且昂贵的,包括频繁局部应用抗菌剂(每日两次),并伴有痛苦的换药。昂贵的高级抗菌剂敷料通过沉积有毒浓度的抗菌剂(通常为100 μg/cm2银/天)而损害伤口愈合。当与生物敷料一起使用时,这些护理标准仍然导致高达20%的感染率。对配方的关键需求未得到满足,这些配方可提供:长期释放抗微生物药物而不会在伤口中产生毒性;支持先进敷料的广泛治疗使用;减少频繁的换药。基于Imbed正在申请专利的纳米膜技术,Imbed生物科学公司成功完成了第一阶段的研究,从而发明和开发了一种独特的银伤口敷料产品概念:具有独特稳定银纳米颗粒的可溶解微膜伤口接触敷料。微膜敷料的一个关键特点是,它含有少量的银,使活性银与伤口床的接触更紧密,对伤口的毒性更小,使用起来更温和。微膜敷料符合伤口床的微轮廓,提供“局部”和“长期”释放活性银离子。低廉的制造成本和低廉的商品成本使微膜敷料成为昂贵的银敷料的一种经济高效的替代品(节省60%左右),用于潮湿和生物伤口敷料。I期研究结果表明,微膜银敷料(1)杀死包括MRSA在内的几种细菌4log10 CFU,(2)提供至少4天的杀菌银的持续释放。
英文摘要
DESCRIPTION (provided by applicant): Clinical infections in burn, trauma and surgical wounds represent a huge economic and health care burden. In the U.S., there is a 2-5% infection rate in surgical wounds and up to a 20% rate in burn wounds. The current standard of care is intensive and expensive, involving frequent topical application of antimicrobials (twice daily) with painful dressing changes. Expensive advanced dressings with antimicrobials impair wound healing by depositing toxic concentrations of antimicrobials (typically >100 μg/cm2 of silver/day). When used with biologic dressings, these standards of care still result in up to 20% infection rate. There is a critical unmet need for formulations that provide: long-term release of antimicrobials without toxic build up in wounds; support broad therapeutic use of advanced dressings; and reduce frequent dressing changes. Successful completion of Phase 1 research at Imbed Biosciences has resulted in the invention and development of a unique silver wound dressing product concept based on Imbed's patent-pending nanofilm technology: dissolvable microfilm wound contact dressing with uniquely stabilized silver nanoparticles. A key feature of the microfilm dressing is that it contains a small quantity of silver that provides more intimate contact of active silver with the wound bed, which is less toxic to the wound and gentler to use. The microfilm dressing conforms to the micro-contours of the wound bed to provide 'localized' and 'long-term' release of active silver ions. Inexpensive fabrication and low cost of goods makes the microfilm dressing a cost-efficient alternative (>60% savings) to expensive silver dressings for use with moist and biologic wound dressings. Results of Phase I research demonstrated that the microfilm silver dressing (1) kills 4 log10 CFU of several bacterial species, including MRSA, (2) provides sustained release of bactericidal silver for at least 4 days,
(3) does not show detectable in-vitro cytotoxicity or in-vivo systemic toxicity, (4) allows normal wound healing by re-epithelialization, and (5) significantly reduces microbial colonization and expedites wound closure under biosynthetic dressings in contaminated murine wounds. Comparison to other silver dressings showed that the microfilm dressing releases up to 100x less silver than most available dressings, provides equivalent or better antibacterial activity, an allows normal wound re-epithelialization unlike some silver dressings. Based on this promising data from Phase 1 research, and enthusiastic feedback from clinicians and potential commercial partners, Phase II research aims to further develop, optimize, and validate the Microfilm Silver Dressing product concept for high-throughput fabrication (Aim 1), broad-spectrum antimicrobial activity (Aim 2), biocompatibility (Aim 3), and porcine wound healing (Aim 4). We have assembled a team of material scientists, microbiologists, and veterinary and medical surgeons, with a history of successful collaboration. Completion of Phase II research will provide optimized design and data sets for microfilm dressings required for manufacturing scale-up and regulatory approval for human clinical trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ultrathin dissolvable antibiofilm wound contact dressing with silver and gallium
-
批准号:10493180
-
项目类别:
-
资助金额:$40.14万
-
财政年份:2021
-
负责人:Ankit Agarwal
-
依托单位:
Ultrathin dissolvable antibiofilm wound contact dressing with silver and gallium
-
批准号:10259892
-
项目类别:
-
资助金额:$40.51万
-
财政年份:2021
-
负责人:Ankit Agarwal
-
依托单位:
Ultrathin dissolvable antibiofilm wound contact dressing with silver and gallium
-
批准号:9621893
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2018
-
负责人:Ankit Agarwal
-
依托单位:
Ultrathin dissolvable antibiofilm wound contact dressing with silver and gallium
-
批准号:10017650
-
项目类别:
-
资助金额:$74.92万
-
财政年份:2018
-
负责人:Ankit Agarwal
-
依托单位:
Antibacterial Molecular Coatings Pre-Fabricated for Biologic Wound Dressings
-
批准号:8253391
-
项目类别:
-
资助金额:$32.65万
-
财政年份:2012
-
负责人:Ankit Agarwal
-
依托单位:
海外基金